Wall Street expects a year-over-year increase in earnings on higher revenues when TransMedics (TMDX) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 2 ...

ANDOVER, Mass., Oct. 15, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with endstage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2024 after market close on Monday, October 28, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listeni ...

Overview of FMR LLC (Trades, Portfolio)'s Recent Transaction On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 2,281,896 shares of TransMedics Group Inc (TMDX, Financial), a leader in advanced organ transplant technology. This move reduced FMR LLC (Trades, Portfolio)'s holdings in the company by 50.82%, leaving them with a total of 2,208,308 shares. The shares were traded at a price of $157 each, reflecting a strategie adjustment in FMR LLC (Trades, ...

TransMedics (TMDX) closed the last trading session at $143.80, gaining 0.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $181.89 indicates a 26.5% upside potential. The average comprises nine short-term price targets ranging from a low of $153 to a high of $208, with a standard deviation of $17.60. While the lowest estimate indicates an increase of 6.4% from the current price le ...

TransMedics (TMDX) shares rallied 10.1% in the last trading session to close at $159.14. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.3% loss over the past four weeks. TransMedics scored a strong price increase driven by investors' optimism following the news of the company joining the S&P SmallCap 600. On Sept. 26, per S&P Dow Jones' press release, Transmedics will replace The Ensign Group in the S&P S ...

sturti Investment Thesis TransMedics (NASDAQ:TMDX) is a company that is revolutionizing the way organs are transported for transplants. This is a statement that puts a lot of weight on the company, but so far, it has proven to be true and sales continue to grow +100% YoY with net margins of 10 to 12%. Despite strong competitive advantages, TMDX is trading at less than 11 times EV/Sales, while recently acquired companies and some competitors are trading at more than 17 times, making it a buying opportunity. ...

ANDOVER, Mass., Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with endstage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York. The fireside chat will take place on Wednesday, September 4, 2024, at 1:05 p.m. Ea ...

A long lead in a niche industry ripe for disruption could make this stock a top performer. For longer than most folks reading this have been alive, Warren Buffett has been getting rich by acting greedy while the rest of the market is fearful. According to one popular indicator, it's nearly time to start acting greedy. A key measure of stock market fear, the CBOE S&P 500 Volatility Index, or VIX, spiked above 60 points on the morning of Monday, Aug. 5. That's higher than it's been since the COVID-19 pandemic ...

TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a short-term bullish trend. A well-liked tool among traders, the 20-day simple moving average offers a look back at a stock's price over a 20-day period. This is very beneficial to short-term traders, as it smooths out short-term price trends and gives more trend reversal signals than longer-term moving averages ...

CatLane Back in October 2023, I was adding aggressively to my TransMedics Group, Inc. (NASDAQ:TMDX) position when the stock dipped into the $30s. I was also adding aggressively before Q1 2024 earnings. Back in March/April, as I was trimming 90-95% of my Celsius Holdings, Inc. (CELH) and Super Micro Computer, Inc. (SMCI) positions, I was using that cash to add to many of my holdings, including TMDX. It became my largest position, and it's been that way for approximately three months. Even though TMDX is up m ...